An international view of hydroxyethyl starches

被引:276
作者
Treib, J
Baron, JF
Grauer, MT
Strauss, RG
机构
[1] Univ Hosp Saarland, Dept Neurol, Intens Stroke Unit, D-66421 Homburg, Germany
[2] Univ Hosp Saarland, Dept Neurol, Intens Care Unit, D-66421 Homburg, Germany
[3] Univ Paris 06, Hop Broussais, Dept Anesthesiol, F-75014 Paris, France
[4] Univ Iowa, Coll Med, Hosp & Clin, DeGowin Blood Ctr ,Dept Pathol, Iowa City, IA 52242 USA
[5] Univ Iowa, Coll Med, Hosp & Clin, DeGowin Blood Ctr ,Dept Pediat, Iowa City, IA 52242 USA
关键词
D O I
10.1007/s001340050833
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. A variety of different HES solutions exist worldwide, which differ greatly in their pharmacological properties. HES is classified according to its manufactured or in vitro molecular weight (MW) into high MW (450-480 kDa), medium MW (200 kDa), and low MW (70 kDa) starch preparations. However, this is not sufficient, because as HES is metabolized in vivo, its MW changes, and it is the in vivo MW which is responsible for the therapeutic and adverse effects, of each HES. The rate of metabolization depends mainly on the degree of hydroxyethyl substitution (ranging from 0.4 to 0.7), and the C2/C6 ratio of hydroxyethylation. A high degree of substitution and a high C2/C6 ratio lead to a slow metabolization of HES, resulting in a large in vivo MW. Slowly degradable high MW HES 450/0.7 and medium MW HES 200/0.62 have a high in vivo MW and are eliminated slowly via the kidneys. As a result, these starches have a relatively long-lasting volume effect, When infusing higher volumes (> 1500 mi) are infused, large molecules accumulate in the plasma. This can result in bleeding complications due to decreased factor VIII/von Willebrand factor, platelet function defects, incorporation into fibrin clots, and an unfavorable effect on rheological parameters. Rapidly degradable medium MW HES 200/05 or low MW HES 70/0.5 are quickly split in vivo into smaller, more favorable molecule sizes, resulting in faster renal elimination, shorter volume effect, and fewer adverse effects on coagulation and rheological parameters. For historical and marketing reasons, only slowly degradable, high MW HES (480/0.7) is available in the United States. In Europe, a large variety of HES solutions are available, dominated by medium MW, easily degradable HES (200/0.5). Because of increasing international competition and the availability of newly developed starches, it is important to be aware of the pharmacological properties of HES and the advantages and disadvantages of the individual preparations.
引用
收藏
页码:258 / 268
页数:11
相关论文
共 79 条
  • [1] PLASMA EXPANDERS AND BLEEDING
    ABRAMSON, N
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 108 (02) : 307 - 307
  • [2] ARKEL YS, 1994, THROMB HAEMOSTASIS, V72, P643
  • [3] LOW-MOLECULAR-WEIGHT HYDROXYETHYL STARCH 6-PERCENT COMPARED TO ALBUMIN 4-PERCENT DURING INTENTIONAL HEMODILUTION
    BARON, JF
    DEKEGEL, D
    PROST, AC
    MUNDLER, O
    ARTHAUD, M
    BASSET, G
    MAISTRE, G
    MASSON, F
    CARAYON, A
    LANDAULT, C
    BARRE, E
    VIARS, P
    [J]. INTENSIVE CARE MEDICINE, 1991, 17 (03) : 141 - 148
  • [4] BATLLE J, 1985, THROMB HAEMOSTASIS, V54, P697
  • [5] BIANCHINE JR, 1987, NEW ENGL J MED, V317, P965
  • [6] INFLUENCE OF VOLUME REPLACEMENT WITH DIFFERENT HES-SOLUTIONS ON MICROCIRCULATORY BLOOD-FLOW IN CARDIAC-SURGERY
    BOLDT, J
    ZICKMANN, B
    RAPIN, J
    HAMMERMANN, H
    DAPPER, F
    HEMPELMANN, G
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1994, 38 (05) : 432 - 438
  • [7] DISSEMINATED INTRAVASCULAR COAGULATION DUE TO INTRAVENOUS ADMINISTRATION OF HETASTARCH
    CHANG, JC
    GROSS, HM
    JANG, NS
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1990, 300 (05) : 301 - 303
  • [8] ULTRASTRUCTURAL BASIS OF MECHANISM OF ROULEAUX FORMATION
    CHIEN, S
    JAN, KM
    [J]. MICROVASCULAR RESEARCH, 1973, 5 (02) : 155 - 166
  • [9] Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients
    Cittanova, ML
    Leblanc, I
    Legendre, C
    Mouquet, C
    Riou, B
    Coriat, P
    [J]. LANCET, 1996, 348 (9042) : 1620 - 1622
  • [10] The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C
    Conroy, JM
    Fishman, RL
    Reeves, ST
    Pinosky, ML
    Lazarchick, J
    [J]. ANESTHESIA AND ANALGESIA, 1996, 83 (04) : 804 - 807